Kynos Therapeutics
Kynos Therapeutics is developing first-in-class small molecule inhibitors of kynurenine monooxygenase (KMO) to target acute and chronic inflammatory disorders. Their therapies aim to reduce systemic inflammation and address the urgent need for new treatments in conditions where current options are limited.
- Biotechnology
Funding
Raised to date
$8.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute and chronic inflammatory disorders lack effective treatments, leaving a significant unmet need for novel therapies that can reduce systemic inflammation. Current treatment options are often limited in their efficacy or associated with significant side effects.
Solution
Kynos Therapeutics develops first-in-class small molecule inhibitors of kynurenine monooxygenase (KMO) to address acute and chronic inflammatory disorders. By inhibiting KMO, their therapies aim to modulate the kynurenine pathway, reducing systemic inflammation and offering a new therapeutic approach. Their lead drug candidate, KNS366, has undergone Phase I clinical trials, demonstrating the potential of KMO inhibition in humans. The company's research leverages a history of KMO biology research and collaboration with GSK to optimize potent and selective KMO inhibitors.
Target Audience
The primary target audience includes patients suffering from acute and chronic inflammatory disorders, as well as healthcare providers seeking novel therapeutic options for these conditions.
Features
- Small molecule KMO inhibitors designed for oral bioavailability
- Selective targeting of the kynurenine pathway to modulate inflammation
- KNS366: Lead drug candidate with Phase I clinical trial data available
- Potential application in acute pancreatitis and other inflammatory conditions